In order to identify potential genetic markers of response to the TKIs across the 115 cell line panel, the growth response to each TKI was correlated in an unbiased manner to mutations or copy number variations in 38 well-known oncogenes and tumour-suppressor genes, including EGFR and HER2, by a type II ANOVA.16HER2 amplification was identified as a drug response marker for all three TKIs, as expected for HER2-targeted therapies (Fig. 4a). This evidence concerns the gene ERBB2 and neoplasm.